Biotech Startups

DIANA Biotechnologies is a Czech biotech company that sells products and services to the life sciences research market through a distributed network of regional distributors and scientific marketplaces.

2 investors

Dignify Therapeutics is developing drug programs that induce on-demand defecation and urination to treat functional bowel and bladder disorders, including incontinence and retention associated with neurological conditions and aging. Its candidates are intended to reduce reliance on bladder catheters, manual bowel programs, and adult wearables, and to lower the risk of related infections and hospitalization.

2 investors

Diligent provides a centralized vendor management platform for clinical trial sponsors to discover, qualify, and oversee vendors, aiming to reduce qualification timelines and mitigate risk. It also maintains VendorBase, a global database where clinical research vendors can get qualified and gain exposure to sponsors seeking partnerships.

2 investors

DINYA DNA builds an enzymatic "Exponential Synthesis" platform that directly synthesizes long, complex double-stranded DNA up to 5kb from a pre-built material library without oligo assembly, delivering custom sequences in 3-10 days. It serves scientists through an Early Access synthesis service, planned to launch in 2026, in the synthetic biology and gene synthesis space.

2 investors

Caidya is a global full-service clinical research organization (CRO) that supports biopharmaceutical companies with clinical trial design, execution, and patient recruitment across more than 40 countries. It provides patient-centric clinical trial solutions and high-quality data delivery across core therapeutic areas.

2 investors

Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle platform to deliver nucleic acids, such as mRNA, to the intestinal epithelium. It focuses on oral mRNA medicines.

2 investors

DNAiTECH develops molecular diagnostic tests for point-of-care applications, including its PLACID platform combining paper-based LAMP-CRISPR technology, serving both medical and agricultural diagnostic markets. The company focuses on accessible diagnostics for conditions including ME/CFS, Long COVID, and veterinary/agritech applications.

2 investors

2 investors

Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation. The company leverages a proprietary drug discovery platform and two decades of expertise to create first-in-class and best-in-class drug candidates.

2 investors

Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies. The company, a spin-out from Aarhus University and Max-Planck Society, builds proprietary platform technology to treat diseases with significant unmet medical need.

2 investors

DropGenie builds a lab automation platform that miniaturizes and parallelizes cell engineering reactions on patented chips, delivering editing reagents into cells at nanoliter volumes. It enables arrayed CRISPR screening and genetic screens using limited patient samples for genomic discovery, cell and gene therapy development, and personalized medicine research.

2 investors

Drug Hunter operates an online platform serving the drug discovery community, publishing authored, reviewed, and edited content along with site features and events. It is supported by a team of authors, reviewers, editors, and support staff.

2 investors

Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD. Its programs aim to clear disease-driving proteins like toxic TDP43 to slow disease progression for patients and their families.

2 investors

Duo Oncology is a clinical-stage company developing tumor-activated prodrug combinations intended to replace toxic multi-agent chemotherapy with single medicines that concentrate activity in tumors. Its lead candidate, DUO-207, combines gemcitabine and paclitaxel into a single-infusion prodrug positioned as a chemotherapy backbone for use with KRAS inhibitors in solid tumors such as pancreatic, lung, and breast cancer.

2 investors

Dxcover provides a platform for rapid development of liquid biopsies to detect cancer and other diseases.

2 investors

Dxome applies clinical research, bioinformatics, data analytics, and molecular biology to genetic diagnostics and personalized treatment. Its work spans genome diagnostics, molecular diagnostics, and genomic analysis technology for healthcare.

2 investors

Dynamic Biosensors develops the heliX biosensor instruments and switchSENSE and single-cell Interaction Cytometry (scIC) technologies for characterizing molecule-molecule and molecule-cell interactions and binding kinetics. Its instruments serve researchers in drug discovery and life sciences studying biophysical molecular interactions; the company was acquired by Bruker in 2024.

2 investors

EarlyDx develops non-invasive liquid biopsy tests aimed at early cancer detection and precision medicine. The company positions its tests as accurate and affordable diagnostics.

2 investors

Eden Bio develops machine-learning technology for genetic engineering and protein yield optimization across food, pharmaceutical, and biofuel industries. The company supports customers through precision fermentation to enable sustainable production processes.

2 investors

Edison Agro Sciences develops bio-based synthetic rubber from sunflower crops as an alternative to petrochemical and natural rubber for industrial applications. The company processes agricultural waste from sunflower farming to create environmentally responsible rubber products for manufacturers seeking to reduce carbon emissions and comply with regulatory requirements.

2 investors

A Berkeley spinout developing a new generation of medicines for the brain and other hard-to-treat tissues using breakthrough science from UC Berkeley and the Innovative Genomics Institute.

2 investors

Edwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.

2 investors

2 investors

Eirion Thera develops therapeutics focused on aesthetic medicine and medical dermatology. It operates in the biotech and pharmaceutical sector targeting dermatological and aesthetic conditions.

2 investors